BDTXBlack Diamond Therapeutics, Inc.

$126M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$70M

Gross Profit

$70M100.0% margin

Operating Income

$55M77.9% margin

Net Income

$57M80.8% margin

EPS (Diluted)

$0.98

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$53M

Free Cash Flow

$53M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$176M

Total Liabilities

$35M

Stockholders' Equity

$142M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$70M	$0	—
Gross Profit	$70M	-$86,000	+81495.3%
Operating Income	$55M	-$20M	+369.3%
Net Income	$57M	-$18M	+410.2%

Revenue Segments

Reportable Segment

$70M100%

BDTX Q1 2025 Earnings — Black Diamond Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena